Clinical Trials
921 trialsControlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
University of Southern California
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Alliance for Clinical Trials in Oncology
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Daiichi Sankyo
ARC-25
Arcus Biosciences, Inc.
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer
City of Hope Medical Center
ReDCoAT
NYU Langone Health
Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients
Memorial Sloan Kettering Cancer Center
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Novartis
THE EFFECT OF WHATSAPP-BASED EX-PLISSIT MODEL SEXUAL COUNSELING ON SEXUAL FUNCTION AND SEXUAL DISTRESS IN BREAST CANCER SURVIVORS
Karamanoğlu Mehmetbey University
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
University of Michigan Rogel Cancer Center
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
Ohio State University Comprehensive Cancer Center
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer
M.D. Anderson Cancer Center
DPDMAX
Centre Antoine Lacassagne
EPIK-B5
Novartis
TTBF
University of California, San Francisco
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
DualityBio Inc.
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Eastern Cooperative Oncology Group
Subito
The Netherlands Cancer Institute
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
National Cancer Institute (NCI)
FRONE
Institut Bergonié
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
STEPS-BC
Wake Forest University Health Sciences
TAILORx
National Cancer Institute (NCI)
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
National Cancer Institute (NCI)
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
National Cancer Institute (NCI)
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity
Universitätsklinikum Hamburg-Eppendorf
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
BREVITY
Rna Diagnostics Inc.
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
NAOMI
Dartmouth-Hitchcock Medical Center
A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
STARTRK-2
Hoffmann-La Roche
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
FEStastic
Amsterdam UMC, location VUmc
Performance of Diffusion-weighted Imaging-based Virtual MR Elastography (vMRE) for Diagnosing Breast Cancer
Yunnan Cancer Hospital
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
PRO-ACTIVE
University of Washington
Efficacy and Safety of 500mg of Fulvestrant
Beth Israel Deaconess Medical Center
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
M.D. Anderson Cancer Center